

CE Announcement

Title – ***“Molidustat for Felines”***

Date and Time of CE Activity – **November 21st, 2024**

Location, including city and state – **Live Webinar**

Overview – Anemia is a common and serious complication in felines with chronic kidney disease (CKD), significantly impacting their quality of life and overall health outcomes. Despite advancements in veterinary medicine, many practitioners still face challenges in accurately diagnosing and managing anemia associated with CKD. The complexity of the condition, combined with the limitations of existing treatment options, underscores the need for improved knowledge and skills among veterinarians in this area. Current standards of care for feline anemia of CKD often involve erythropoiesis-stimulating agents (ESAs) and iron supplementation; however, these therapies have notable drawbacks, including potential adverse effects and inadequate response in some patients. The recent conditional approval of Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, presents a new avenue for treatment but requires careful evaluation of the data supporting its efficacy and safety. This activity aims to enhance veterinary practitioners' understanding of the diagnostic criteria and pathophysiology of anemia in CKD, recognize the limitations of current treatment standards, critically evaluate the data for Molidustat, and apply this information to make informed clinical recommendations for managing feline patients suffering from anemia due to CKD.

Overall Activity Goal - The goal of this activity is to educate pharmacists about the use of Molidustat in felines.

Target Audience – This activity is primarily intended for pharmacists, technicians, veterinarians, & students from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant (pharmacists, students, & technicians) should be able to:

Objectives:

Pharmacist:

1. Describe the basic diagnostic criteria and pathophysiology for anemia of CKD in felines.
2. Recognize current standards of care for feline anemia of CKD as well as their drawbacks.
3. Understand the mechanism of action of Molidustat.
4. Recall Molidustat drug information in order to make rational clinical recommendations for felines with anemia of CKD.
5. Define the current regulatory status of and the limitations of prescribing Molidustat.

Pharmacy Technicians:

1. Recognize current standards of care for feline anemia of CKD as well as their drawbacks.
2. Understand the mechanism of action of Molidustat.
3. Define the current regulatory status of and the limitations of prescribing Molidustat



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1 contact hour of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via utcop.learningexpressce.com within 14 days of the scheduled activity date. UAN: 0064-9999-24-237-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor upon completing the evaluation and CPE claim. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information:

	Member	Non-Member
Pharmacist	\$40	\$50
Technician	\$25	\$30
Student Pharmacist (no CE)	\$5	\$10

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Garrett Snowden and Dr. Tanner Trantham

Relevant financial disclosures: None

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of

Continuing Professional Development at jwheele4@uthsc.edu. The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions